Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1979 May;24(2):346–351. doi: 10.1128/iai.24.2.346-351.1979

Evaluation of a ribosomal vaccine against pertussis.

L H Field, C D Parker, C R Manclark, L J Berry
PMCID: PMC414307  PMID: 222684

Abstract

A crude ribosomal vaccine derived from Bordetella pertussis administered to ICR and N:NIH (SW) strains of mice protected them effectively against a standardized intracranial challenge. The dose of vaccine that protected half the mice was less for N:NIH (SW) than for ICR mice and compared favorably with a killed reference vaccine. Ribosomes prepared from bacteria ground with washed sea sand were more immunogenic than those obtained by rupture with alumina or with a Braun homogenizer. The protective effect of the crude ribosomes was not an innate part of the organelle but was due to a substance or substances that could be removed from them by a 1 M NH4Cl wash. The material in the wash was highly immunogenic and retained both the histamine-sensitizing and leukocytosis-promoting properties. It lost much of the dermonecrotic activity and was poorly pyrogenic in rabbits. The most potent pyrogen was present in the washed ribosomes, which apparently, retained the endotoxic components of the cell wall. The best vaccines permitted acceptable weight gain in the immunized mice.

Full text

PDF
351

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Field L. H., Parker C. D. Pertussis outbreak in Austin and Travis County, Texas, 1975. J Clin Microbiol. 1977 Aug;6(2):154–160. doi: 10.1128/jcm.6.2.154-160.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Hewlett E. L., Urban M. A., Manclark C. R., Wolff J. Extracytoplasmic adenylate cyclase of Bordetella pertussis. Proc Natl Acad Sci U S A. 1976 Jun;73(6):1926–1930. doi: 10.1073/pnas.73.6.1926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hoops P., Prather N. E., Berry J., Ravel J. M. Evidence for an extrinsic immunogen in effective ribosomal vaccines from Salmonella typhimurium. Infect Immun. 1976 Apr;13(4):1184–1192. doi: 10.1128/iai.13.4.1184-1192.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  5. Manclark C. R. The current status of pertussis vaccine: an overview. Adv Appl Microbiol. 1976;20:1–7. doi: 10.1016/s0065-2164(08)70105-9. [DOI] [PubMed] [Google Scholar]
  6. Manclark C. R., Urban M. A., Summers E. P., Vickers J. H. Assay of pertussis vaccine toxicity by a rat-paw-oedema method. J Med Microbiol. 1977 Feb;10(1):115–120. doi: 10.1099/00222615-10-1-115. [DOI] [PubMed] [Google Scholar]
  7. Morse S. I. Biologically active components and properties of Bordetella pertussis. Adv Appl Microbiol. 1976;20:9–26. doi: 10.1016/s0065-2164(08)70106-0. [DOI] [PubMed] [Google Scholar]
  8. Stainer D. W., Scholte M. J. A simple chemically defined medium for the production of phase I Bordetella pertussis. J Gen Microbiol. 1970 Oct;63(2):211–220. doi: 10.1099/00221287-63-2-211. [DOI] [PubMed] [Google Scholar]
  9. YOUMANS A. S., YOUMANS G. P. IMMUNOGENIC ACTIVITY OF A RIBOSOMAL FRACTION OBTAINED FROM MYCOBACTERIUM TUBERCULOSIS. J Bacteriol. 1965 May;89:1291–1298. doi: 10.1128/jb.89.5.1291-1298.1965. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES